Creative Testing Solutions

What it reported doing in 2025

Donor testing blood donor and plasma testing services provided by creative testing solutions ("cts") are essential to ensuring the safety of the nation's blood and plasma supply. These testing activities are absolutely necessary and mandated by the united states food and drug administration ("fda") to provide a safe blood product for transfusion to patients and to ensure safety of plasma products. Due to the significant health risks associated with the use of human blood and blood components, it is critical for public safety purposes that blood be properly tested before being introduced into the healthcare system for use by patients. A safe blood supply is critical to the well-being of the nation's healthcare system and its patients. The significance of the testing of blood for public safety is even more pronounced in this age of threats from pandemics and terrorism. Creative testing solutions operated eight donor testing laboratories in 2025. Our first established laboratory is in tempe, Arizona. The additional laboratories are located in bedford, Texas, charlotte, North Carolina, st. Louis, Missouri, st. Petersburg, Florida, san marcos, Texas, austin, Texas, and memphis, Tennessee. These locations are strategically positioned near major airports in phoenix, dallas, charlotte, st. Louis and tampa. The five dtl laboratories are food and drug administration (fda) registered facilities and hold current certifications for the clinical laboratory improvement act (clia) as well as accreditation with the american association of blood banks (aabb), the New York state department of health, California department of health services. Personnel at the tampa laboratory are licensed with the state of Florida agency for health care administration. In addition to donor specimen testing, the laboratories participate in clinical evaluation of reagents, test kits, and equipment. Cts provides the highest quality in testing and service. The laboratories maintain internal quality control programs and participate voluntarily in external quality control programs. Blood specimens are processed utilizing state of the art technology with fda licensed test kits and reagents. All laboratories are equipped with multiple and redundant instruments required for routine processing. Additionally, each facility acts as a backup laboratory to the other cts labs. Special testing our special testing laboratory in the phoenix area performs confirmatory and supplemental testing of donor samples as well as non-donation testing such as donor re-entry, post exposure and donor follow-up. It also provides testing for eye banks, tissue banks and cord blood centers. The special testing laboratories also comply with clia, fda, ca, ny, md, and fl state regulations.

Financial Efficiency

• Mission deployment rate: 81.7%; rating input score 82
• Program expense ratio: 91.9%; rating input score 92
• Fundraising efficiency: Limited

Transparency & Controls

• Consistency checks: 100%; rating input score 100; 66th percentile among comparable filings
• Pay-setting controls: 6 of 6 controls in place; rating input score 100
  • Compensation committee: Pass
  • Independent consultant: Pass
  • Other Form 990s reviewed: Pass
  • Written employment contract: Pass
  • Compensation survey or study: Pass
  • Board or committee approval: Pass
• Foreign activity oversight: Limited
• Grant itemization coverage: Limited
• Major donor itemization: Limited
• Related-party transparency: Limited

Accountability

• Independent voting board: 100%; rating input score 100; 65th percentile among comparable filings
• Governance controls: 9 of 9 controls in place; rating input score 100
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: Pass
  • Other executive compensation review process: Pass
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Pass
  • Independent financial-statement audit: Pass

Sustainability

• Operating margin: 11.2%; rating input score 73; 73rd percentile among comparable filings
• Total-asset coverage ratio: 0.59; rating input score 17; 17th percentile among comparable filings
• Liabilities to assets ratio: 0.43; rating input score 47; 47th percentile among comparable filings
• Officer compensation ratio: 1.8%; rating input score 65; 65th percentile among comparable filings

Growth

• Program expense growth: 7.1% per year; rating input score 100; 53rd percentile among comparable filings
• Revenue growth: 7.2% per year; rating input score 100; 56th percentile among comparable filings
• Asset growth: 9.9% per year; rating input score 100; 68th percentile among comparable filings